PREPARATION AND CHARACTERIZATION OF SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEM (SMEDDS) OF CISPLATIN FOR ORAL USE IN OVARIAN CANCER TREATMENT

Akartas, Irfan/0000-0002-8152-5591WOS: 000518225300018Cisplatin is an antineoplastic drug, used for the treatment of ovarian cancer. SMEDDS has many advantages such as enhanced bioavailability, lymphatic targeting and ease of manufacture. the main objective of this study was to prepare and characterize Cisplatin loaded SMEDDS formulation and to evaluate antitumoral activity with cell viability studies. Cisplatin SMEDDS formulation was prepared and characterized physicochemically. in vitro release studies and cell viability studies were performed and evaluated. the mean droplet size of Cisplatin SMEDDS was measured as 25.4 +/- 1.9 nm and PDI was 0.241 +/- 0.018. Refractive index of the formulation was measured as 1.471 +/- 0.001. pH values of Cisplatin SMEDDS (dilution ratio 1 : 10 water) were measured as 5.84 +/- 0.09 and (dilution ratio 1 : 10 pH 6.8 PBS) 6.51 +/- 0.14. the viscosity of formulation was measured as 284 mPa. According to in vitro release studies, 78.17% of Cisplatin was released from Cisplatin SMEDDS. the formulation showed a cytotoxic effect to A2780 cells; vitality were found 20.26% at 0.02 mu g/mL. It was concluded that Cisplatin SMEDDS could be beneficial for the treatment of ovarian cancer and it could be a promising alternative due to its enhanced bioavailability

EVALUATION OF MICROEMULSION FORMULATIONS FOR PARENTERAL DRUG DELIVERY OF APROTININ: FORMULATION, DESIGN AND STABILITY STUDIES

WOS: 00020934590008

Development and in vitro Evaluation of Theophylline Loaded Matrix Tablets Prepared with Direct Compression

WOS: 000392938000006The objectives of the present study are to develop novel sustained release matrix tablets of theophylline and to evaluate release properties and kinetic behaviour of these tablets. The formulations have been prepared in order to improve their dissolution properties in terms of providing better oral absorption of theophylline. Therefore, the effects of the components' nature and their proportion in the release rate were investigated. Theophylline loaded tablets were prepared with direct compression using Compritol (R) ATO 33 and Hydroxypropyl methylcellulose (HPMC E-50) with different amounts and then they were evaluated for their in vitro drug release profiles. According the evaluation of drug release profiles, it has seen that Compritol (R) ATO 33 and HPMC-E50 ratio changed the release profile of theophylline. The dissolution of tablets was determined by using USP XXIII dissolution testing apparatus II. Matrix tablets were carried out in pH 4.5 phosphate buffer, as dissolution medium, for 8 h. Te-3, Te-4 and Te-7 formulations ensure the criteria of The United States Pharmacopeia XXIII for theophylline extended release capsules (Test 2 criteria, apparatus II). The release data fitted to various mathematical models such as, zero order, first order, Higuchi, Hixson Crowell and Korsmeyer-Peppas for the evaluation of the kinetics and mechanism of the drug release. The release mechanism of matrix tablets followed first order release kinetics. The results of the study indicate that new matrix tablets can be promising alternative for the other oral formulations of theophylline.Ege University Scientific Research ProjectsEge University [04/ECZ/016]This study was supported by Ege University Scientific Research Projects No: 04/ECZ/016

EVALUATION OF TRANSDERMAL ABSORPTION AND ANTI-INFLAMMATORY AND ANALGESIC ACTIVITIES OF NAPROXEN THROUGH RAT SKIN: EX VIVO AND IN VIVO

WOS: 00020934590009